<DOC>
	<DOCNO>NCT02402439</DOCNO>
	<brief_summary>The goal trial gain initial clinical experience regard safety efficacy treat type I diabetes people receive kidney transplant transplant islet new transplant site stomach ( gastrointestinal submucosa ) . A total 6 patient enrol study follow period 3 year last islet transplant .</brief_summary>
	<brief_title>Treatment Type I Diabetes Islet Transplantation Into Gastric Submucosa Study Protocol</brief_title>
	<detailed_description>Pancreatic islet transplantation offer minimally invasive approach restore normoglycemia type 1 diabetic avoid hypoglycemic complication observe intensive insulin therapy surgical complication associate pancreas transplantation . Although significant progress make clinical islet transplantation , overall outcome remain suboptimal since many patient lose insulin independence year transplantation multiple donor usually need achieve independence . The cause progressive loss function multifactorial , mount evidence suggest much islet loss transplant directly relate intraportal transplant site use clinical islet transplantation . Intravascular infusion islet trigger severe , non-specific inflammatory response ( immediate blood-mediated inflammatory reaction , IBMIR ) destroy least 50 % islet mass . The engraftment survive islet compromise relatively hypoxic portal venous environment , infuse islet expose potentially toxic level immunosuppressive agent absorb gut portal circulation . Together , characteristic contribute early well late loss islet function transplantation . The gastrointestinal submucosa newly describe transplant site support islet engraftment avoid many drawback associate intraportal infusion . In addition , site easily accessible via upper endoscopy submucosal injection procedure safe technically straightforward . The aim prospective , single-center trial provide initial clinical experience regard safety efficacy endoscopic gastric duodenal submucosal islet transplantation type I diabetic patient kidney allograft . A total 6 patient recruited trial . The investigator follow standardized islet manufacturing protocols thymoglobulin-based induction immunosuppressive regimen develop Clinical Islet Transplant consortium ( CIT ) . Outcomes include safety measure , glycemic control insulin use , metabolic assessment graft function , allo/auto-immune response , protocol biopsy assess graft rejection/inflammation . The investigator believe novel approach islet transplantation potential significantly improve current islet transplantation outcomes enhance islet engraftment long-term function .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<mesh_term>Pancreatin</mesh_term>
	<criteria>1 . Male female subject age 18 70 year age . 2 . Subjects able provide write informed consent comply study procedure . 3 . Clinical history compatible T1D ( onset &lt; 40 yr old insulin dependent &gt; 5 yrs enrollment . 4 . Absent stimulate cpeptide ( &lt; 0.3 ng/mL ) response ( Boost® 6 mL/kg BW maximum 360 mL ; another equivalent product ) , measure 60 90 min start consumption . 5 . Subjects &gt; 3 month postrenal transplant take appropriate calcineurin inhibitor ( CNI ) base maintenance immunosuppression ( [ tacrolimus alone conjunction sirolimus , mycophenolate mofetil , myfortic , azathioprine ; cyclosporine conjunction sirolimus , mycophenolate mofetil , myfortic ± Prednisone ≤ 10 mg/day ) . 6 . Stable renal function define creatinine one third great average creatinine determination perform 3 previous month prior islet transplant , rejection , obstruction infection rule . 7 . Reduced awareness hypoglycemia manifest Clarke score &gt; 4 least 1 episode severe hypoglycemia past 12 month prior study enrollment . This criterion require involvement intensive diabetes management direction endocrinologist , diabetologist , diabetes specialist prior study enrollment . Intensive diabetes management define selfmonitoring glucose value less 3 time day average week administration three insulin injection day insulin pump therapy . Severe hypoglycemia define event one follow symptom : memory loss ; confusion ; uncontrollable behavior ; irrational behavior ; unusual difficulty awaken ; suspect seizure ; seizure ; loss consciousness ; visual symptom , associate either BG level &lt; 54 mg/dl [ 3.0 mmol/L ] prompt recovery oral carbohydrate , IV glucose , glucagon administration . OR In subject meeting hypoglycemia option , HbA1c ≥ 7.5 despite intensive diabetes management define . 1 . Weight 100 kg body mass index ( BMI ) &gt; 30 kg/m2 . 2 . Insulin requirement &gt; 1.0 IU/kg/day &lt; 15 U/day . 3 . Other ( nonkidney ) organ transplant except prior fail pancreatic graft graft failure attribute thrombosis within first 4 week technical reason require graft pancreatectomy ; graft pancreatectomy occur 6 month prior enrollment . 4 . Untreated unstable proliferative diabetic retinopathy . 5 . Blood Pressure : SBP &gt; 160 mmHg DBP &gt; 100 mmHg despite treatment antihypertensive agent . 6 . Calculated GFR ≤ 40 mL/min/1.73 m2 use subject 's measure serum creatinine Chronic Kidney Disease Epidemiology Collaboration ( CKDEPI ) equation . ( 59 ) 7 . Proteinuria ( albumin/creatinine ratio ACr &gt; 300mg/g ) new onset since kidney transplantation . 8 . Calculated panelreactive antiHLA antibody &gt; 50 % . Subjects calculate panel reactive antiHLA antibody ≤ 50 % exclude follow detect : Positive crossmatch Islet donordirected antiHLA antibody detect Luminex® Single Antigen/specificity bead assay include weakly reactive antibody would detect flow crossmatch 9 . For female subject : Positive pregnancy test , presently breastfeed , unwillingness use effective contraceptive measure duration study 4 month discontinuation . For male subject : intent procreate duration study within 4 month discontinuation unwillingness use effective measure contraception . Oral contraceptive , Norplant® , DepoProvera® , barrier device spermicide acceptable contraceptive method ; condom use alone acceptable . 10 . Active infection include hepatitis B , hepatitis C , HIV , TB . A positive skin test ( PPD ) exclusion , follow QuantiFERON® gold assay . 11 . Negative screen EBV IgG . 12 . Invasive Aspergillus , Histoplasmosis , Coccidioidomycosis infection within 1 year prior study entry . 13 . Any history malignancy except completely resect squamous basal cell carcinoma skin . 14 . Known active alcohol substance abuse . 15 . Severe coexist cardiac disease , characterize one condition : Recent MI ( within past 6 month ) , Evidence ischemia functional cardiac exam within last year , Left ventricular ejection fraction &lt; 30 % , Valvular disease require replacement prosthetic valve . 16 . Persistent elevation liver function test time study entry . Persistent SGOT ( AST ) , SGPT ( ALT ) , alkaline phosphatase value &gt; 1.5 , total bilirubin &gt; 1 time normal upper limit exclude subject . 17 . Active infection ( except mild skin nail fungal infection ) . 18 . Acute chronic pancreatitis . 19 . Active peptic ulcer disease gastritis , symptomatic gallstone , portal hypertension . 20 . Treatment antidiabetic medication insulin within 4 week enrollment . 21 . Use investigational agent within 4 week enrollment . 22 . Administration live attenuate vaccine ( ) within 2 month enrollment . 23 . Any medical condition , opinion investigator , interfere safe study completion . 24 . Positive screen BK viremia time screen . 25 . Untreated hyperlipidemia TC &gt; 200 mg/dL , TGC &gt; 200 mg/dL , LDL &gt; 130 mg/dL</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Type 1 diabetes</keyword>
	<keyword>diabetes mellitus</keyword>
	<keyword>pancreatic islet transplant</keyword>
	<keyword>beta cell replacement</keyword>
</DOC>